索拉非尼固体分散体的制备及性质研究

单兴杰; 闫占宽; 于超峰; 李传筠

doi:10.3969/j.issn.1006-0111.2016.04.009

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

索拉非尼固体分散体的制备及性质研究

单兴杰, 闫占宽, 于超峰, 李传筠

文章导航 > 药学实践与服务 > 2016 > 34(4): 320-323,342

单兴杰, 闫占宽, 于超峰, 李传筠. 索拉非尼固体分散体的制备及性质研究[J]. 药学实践与服务, 2016, 34(4): 320-323,342. doi: 10.3969/j.issn.1006-0111.2016.04.009

引用本文:

单兴杰, 闫占宽, 于超峰, 李传筠. 索拉非尼固体分散体的制备及性质研究[J]. 药学实践与服务, 2016, 34(4): 320-323,342. doi: 10.3969/j.issn.1006-0111.2016.04.009

SHAN Xingjie, YAN Zhankuan, YU Chaofeng, LI Chuanjun. The preparation and characterization of sorafenib solid dispersion[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 320-323,342. doi: 10.3969/j.issn.1006-0111.2016.04.009

Citation:

SHAN Xingjie, YAN Zhankuan, YU Chaofeng, LI Chuanjun. The preparation and characterization of sorafenib solid dispersion[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 320-323,342. doi: 10.3969/j.issn.1006-0111.2016.04.009

索拉非尼固体分散体的制备及性质研究

doi: 10.3969/j.issn.1006-0111.2016.04.009

江苏恒瑞医药股份有限公司, 江苏连云港 222000

The preparation and characterization of sorafenib solid dispersion

Jiang Su Heng Rui Medicine Co., Ltd., Lianyungang 222047, China

摘要: 目的制备索拉非尼（sorafenib，SFN）/介孔硅的固体分散体，并进行体内外性质研究。方法利用溶剂挥发法制备固体分散体，以溶出度为指标筛选药物和介孔硅比例；采用差示扫描量热法（DSC）和粉末X射线衍射（XRD）技术，考察药物存在状态及物理稳定性；通过电镜观察样品形貌；以大鼠为实验动物，以自制SFN粉末为对照，对固体分散体进行体内药动学研究。结果原料药为结晶态，溶出度<10%；随着介孔硅的比例增大，固体分散体的溶出度增加，当SFN与介孔硅的比例为1：5时，SFN以非晶态存在，溶出度>90%，在6个月的加速实验中，药物存在状态和溶出度未见明显改变。固体分散体组的c_max是SFN粉末组的1.8倍，相对生物利用度为175%。结论 SFN/介孔硅固体分散体物理稳定性良好，能提高SFN的溶出度，改善其口服吸收效果。
- 索拉非尼 /
- 介孔硅 /
- 固体分散体 /
- 溶出度 /
- 稳定性 /
- 生物利用度
Abstract: Objective To prepare sorafenib (SFN)/mesoporous silica solid dispersion (SD) and investigate characteristics in vitro and in vivo. Methods The SD was prepared by solvent evaporation method; the optimal ratio of SFN to mesoporous silica was determined by examining the dissolution of formula, the drug state and physical stability of SD were examined by DSC and XRD; the surface morphology was characterized by electron microscope; the pharmacokinetics of SD was studied for the solid dispersion which compared with SFN powders in vivo study using rats. Results SFN raw drug was crystalline and its dissolution was <10%; the dissolution of SD increased with an increase in amount of mesoporous silica; when the ratio of SFN to mesoporous silica was 1:5, drug in SD was non-crystalline state and the dissolution was >90%. The physical state and dissolution of SFN in SD were hardly changed during the six months accelerated test. The c_max of SD group was 1.8 times that of powder group, relative bioavailability was 175%. Conclusion The physical stability of self-preparing solid dispersions is good, the dissolution and oral absorption are improved by solid dispersion.
- sorafenib /
- mesoporous silica /
- solid dispersion /
- dissolution /
- stability /
- bioavailability

[1]	Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66(24):11851-11858.
[2]	Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma[J]. Biologics, 2008, 12(4):779-788.
[3]	Wang XQ, Fan JM, Liu YO et al. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat[J]. Int J Pharm, 2011, 419(1-2):339-346.
[4]	Kim MS. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs[J]. Artif Cells Nanomed Biotechnol, 2013, 41(6):363-367.
[5]	Wang L, Cui FD, Sunada H. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method[J]. Chem Pharm Bull, 2006, 54(1):37-43.
[6]	Charnay C, Bégu S, Tourné-Péteilh C, et al. Inclusion of ibuprofen in mesoporous templated silica:drug loading and release property[J]. Eur J Pharm Biopharm. 2004, 57(3):533-540.
[7]	Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celecoxib:the role of thermodynamic quantities and molecular mobility[J]. Mol Pharm, 2004, 1(6):406-413.
[8]	Salonen J, Laitinen L, Kaukonen AM, et al. Mesoporous silicon microparticles for oral drug delivery:loading and release of five model drugs[J]. J Control Release, 2005, 108(2-3):362-374.
[9]	Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice[J]. J Pharm Biomed Anal, 2009, 49(4):1109-1114.
[10]	Wang XQ, Dai JD, Zhang H, et al. Absorption mechanism of cyclosporine A loaded pH-sensitive nanoparticles in rats[J]. J Nanosci Nanotechnol, 2008, 8(5):2422-2431.
[11]	Miller DA, Di Nunzio JC, Yang W, et al. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption[J]. Pharm Res, 2008, 25(6), 1450-1459.
[12]	Janssens S, De Zeure A, Paudel A, et al. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions:a case study with itraconazole and Eudragit E100[J]. Pharm Res, 2010, 27(5), 775-785.

[1]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
[2]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
[3]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[4]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[5]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[6]	毛智毅, 王筱燕, 陈晓颖, 汤逸斐. 度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032

点击查看大图

计量

文章访问数: 3255
HTML全文浏览量: 302
PDF下载量: 914
被引次数: 0

索拉非尼固体分散体的制备及性质研究

doi: 10.3969/j.issn.1006-0111.2016.04.009

江苏恒瑞医药股份有限公司, 江苏连云港 222000

收稿日期: 2015-09-09
修回日期: 2016-01-14

关键词:

索拉非尼 /

介孔硅 /

固体分散体 /

溶出度 /

稳定性 /

生物利用度

摘要: 目的制备索拉非尼（sorafenib，SFN）/介孔硅的固体分散体，并进行体内外性质研究。方法利用溶剂挥发法制备固体分散体，以溶出度为指标筛选药物和介孔硅比例；采用差示扫描量热法（DSC）和粉末X射线衍射（XRD）技术，考察药物存在状态及物理稳定性；通过电镜观察样品形貌；以大鼠为实验动物，以自制SFN粉末为对照，对固体分散体进行体内药动学研究。结果原料药为结晶态，溶出度<10%；随着介孔硅的比例增大，固体分散体的溶出度增加，当SFN与介孔硅的比例为1：5时，SFN以非晶态存在，溶出度>90%，在6个月的加速实验中，药物存在状态和溶出度未见明显改变。固体分散体组的c_max是SFN粉末组的1.8倍，相对生物利用度为175%。结论 SFN/介孔硅固体分散体物理稳定性良好，能提高SFN的溶出度，改善其口服吸收效果。